Literature DB >> 21346856

Therapeutic options for eosinophilic esophagitis.

Jeffrey A Alexander1, David A Katzka.   

Abstract

Entities:  

Year:  2011        PMID： 21346856      PMCID： PMC3038320     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  10 in total

1.  Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors:  Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

2.  Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate.

Authors:  Matthew Remedios; Catherine Campbell; Dianne M Jones; Paul Kerlin
Journal:  Gastrointest Endosc       Date:  2006-01       Impact factor: 9.427

3.  Treatment of eosinophilic esophagitis: is oral viscous budesonide superior to swallowed fluticasone spray?

Authors:  Somashekar G Krishna; Bobby R Kakati; Kevin W Olden; Daniel K Brown
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

4.  Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis.

Authors:  Alex Straumann; Sebastien Conus; Lukas Degen; Stephanie Felder; Mirjam Kummer; Hansjürg Engel; Christian Bussmann; Christoph Beglinger; Alain Schoepfer; Hans-Uwe Simon
Journal:  Gastroenterology       Date:  2010-08-01       Impact factor: 22.682

5.  A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis.

Authors:  Michael R Konikoff; Richard J Noel; Carine Blanchard; Cassie Kirby; Sean C Jameson; Bridget K Buckmeier; Rachel Akers; Mitchell B Cohen; Margaret H Collins; Amal H Assa'ad; Seema S Aceves; Philip E Putnam; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

6.  Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis.

Authors:  Scott Pentiuk; Phillip E Putnam; Margaret H Collins; Marc E Rothenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

7.  Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children.

Authors:  Elizabeth T Schaefer; Joseph F Fitzgerald; Jean P Molleston; Joseph M Croffie; Marian D Pfefferkorn; Mark R Corkins; Joel D Lim; Steven J Steiner; Sandeep K Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2008-02       Impact factor: 11.382

8.  Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis.

Authors:  Richard J Noel; Philip E Putnam; Margaret H Collins; Amal H Assa'ad; Jesus R Guajardo; Sean C Jameson; Marc E Rothenberg
Journal:  Clin Gastroenterol Hepatol       Date:  2004-07       Impact factor: 11.382

9.  Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series.

Authors:  A J Lucendo; J M Pascual-Turrión; M Navarro; C Comas; P Castillo; A Letrán; M T Caballero; J Larrauri
Journal:  Endoscopy       Date:  2007-09       Impact factor: 10.093

10.  3-yr-follow-up of topical corticosteroid treatment for eosinophilic esophagitis in adults.

Authors:  Emelie F Helou; Julie Simonson; Amindra S Arora
Journal:  Am J Gastroenterol       Date:  2008-07-12       Impact factor: 10.864
  10 in total
  3 in total

Review 1.  Pediatric eosinophilic esophagitis: updates for the primary care setting.

Authors:  Melanie A Ruffner; Jonathan M Spergel
Journal:  Curr Opin Pediatr       Date:  2018-12       Impact factor: 2.856

Review 2.  Eosinophilic Esophagitis in Children.

Authors:  Melanie A Ruffner; Jonathan M Spergel
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

3.  Experimental and molecular modeling approach to optimize suitable polymers for fabrication of stable fluticasone nanoparticles with enhanced dissolution and antimicrobial activity.

Authors:  Shaimaa Ahmed; Thirumala Govender; Inamullah Khan; Nisar Ur Rehman; Waqar Ali; Syed Muhammad Hassan Shah; Shahzeb Khan; Zahid Hussain; Riaz Ullah; Mansour S Alsaid
Journal:  Drug Des Devel Ther       Date:  2018-02-05       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.